Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies

Bipolar Disorder

Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review

doi: 10.1016/j.euroneuro.2019.02.003.

Psychosis and Schizophrenia

Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials

Lancet Psychiatry

Højlund M, Kemp AF, Haddad PM, Neill JC, Correll CU

doi: 10.1016/S2215-0366(21)00078-X

Bipolar Disorder

Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder-A critical review of the evidence

Bipolar Disord.

Boyce P, Irwin L, Morris G, Hamilton A, Mulder R, Malhi GS, Porter RJ

doi: 10.1111/bdi.12698.

Psychosis and Schizophrenia

Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis

Lancet Psychiatry.

Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, Malhotra AK, Correll CU, Kane JM

doi: 10.1016/S2215-0366(20)30264-9.

Psychosis and Schizophrenia

Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis

Acta Psychiatr Scand.

Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, Sommer IEC, Leucht S, Kahn RS, Luykx JJ

doi: 10.1111/acps.12954.

DementiaPsychosis and Schizophrenia

Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials

Lancet Psychiatry.

Schneider-Thoma J, Efthimiou O, Huhn M, Krause M, Reichelt L, Röder H, Davis JM, Salanti G, Leucht S

doi: 10.1016/S2215-

Psychosis and Schizophrenia

Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia

JAMA Psychiatry.

Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H

doi: 10.1001/jamapsychiatry.

Bipolar Disorder

Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis

J Affect Disord.

Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G

doi: 10.1016/j.jad.2020.03.030.

Psychosis and Schizophrenia

Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients

Int J Clin Pract.

Mohr P, Knytl P, Voráčková V, Bravermanová A, Melicher T

doi: 10.1111/ijcp.12997.

Related content

Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review

Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials

Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder-A critical review of the evidence

Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis

Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis

Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials

Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia

Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis

Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients

Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia